0000950103-16-016564.txt : 20160926 0000950103-16-016564.hdr.sgml : 20160926 20160926172227 ACCESSION NUMBER: 0000950103-16-016564 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20160926 FILED AS OF DATE: 20160926 DATE AS OF CHANGE: 20160926 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Biotie Therapies Corp. CENTRAL INDEX KEY: 0001579695 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: H9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37423 FILM NUMBER: 161902936 BUSINESS ADDRESS: STREET 1: JOUKAHAISENKATU 6 CITY: TURKU STATE: H9 ZIP: FI-20520 BUSINESS PHONE: 358-2-274-8900 MAIL ADDRESS: STREET 1: JOUKAHAISENKATU 6 CITY: TURKU STATE: H9 ZIP: FI-20520 6-K 1 dp68929_6k.htm FORM 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of September, 2016

 

Commission File Number: 001-37423

 

Biotie Therapies Oyj

(Exact name of registrant as specified in its charter)

 

Biotie Therapies Corp.

(Translation of registrant’s name into English)

 

Joukahaisenkatu 6, FI-20520

Turku, Finland

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F x   Form 40-F  

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Yes     No x

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

Yes   No x

  

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    BIOTIE THERAPIES CORP.
     
      By: /s/ Kristian Rantala
        Name: Kristian Rantala
        Title: Chief Financial Officer

Date: September 26, 2016

 

 
 

 

EXHIBIT INDEX

 

Exhibit Number Description
99.1 Stock Exchange Release dated  September 26, 2016 (9:30 a.m. EET):  The Arbitral Tribunal has confirmed Acorda Therapeutics, Inc.’s redemption right regarding the shares in Biotie Therapies Corp. and public trading in the shares has been terminated

 

 

 EX-99.1 2 dp68929_ex9901.htm EXHIBIT 99.1

Exhibit 99.1

 

BIOTIE THERAPIES CORP.          STOCK EXCHANGE RELEASE   26 September 2016, at 9.30 a.m. (EET)


 

THE ARBITRAL TRIBUNAL HAS CONFIRMED ACORDA THERAPEUTICS, INC.'S REDEMPTION RIGHT REGARDING THE SHARES IN BIOTIE THERAPIES CORP. AND PUBLIC TRADING IN THE SHARES HAS BEEN TERMINATED

 

The Arbitral Tribunal appointed by the Redemption Committee of the Finland Chamber of Commerce has today confirmed that Acorda Therapeutics, Inc. (Nasdaq: ACOR) (“Acorda”) has the right to redeem the minority shares in Biotie Therapies Corp. (Nasdaq Helsinki: BTH1V) (“Biotie”) and that Acorda has the right to obtain title to the minority shares by lodging a security approved by the Arbitral Tribunal for the payment of the redemption price and the interest accruing thereon.

 

Pursuant to the confirmation of the redemption right, Nasdaq Helsinki Ltd has terminated public trading in Biotie's shares today at 9.05 a.m. The lodging of the security, the transfer of title to Acorda and the subsequent delisting of Biotie shares will be announced in due course through a separate stock exchange release.

Turku, 26 September 2016

 

Biotie Therapies Corp.

Antero Kallio
CEO

 

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

 

DISTRIBUTION:
www.biotie.com
Nasdaq Helsinki Ltd
Main Media

 

INFORMATION REGARDING BIOTIE

 

Biotie is a biopharmaceutical company focused on products for neurodegenerative and psychiatric disorders. Biotie's development has delivered Selincro (nalmefene) for alcohol dependence, which received European marketing authorization in 2013 and is currently being rolled out across Europe by partner H. Lundbeck A/S. The current development products include tozadenant for Parkinson's disease, which is in Phase 3 development, and two additional compounds which are in Phase 2 development for cognitive disorders including Parkinson's disease dementia, and primary sclerosing cholangitis (PSC), a rare fibrotic disease of the liver. Biotie is a part of Acorda Therapeutics Inc. Group ("Acorda") and its shares, excluding of those owned by Acorda, are currently subject to a redemption process in accordance with the Finnish Companies Act.

 

For more information, please visit www.biotie.com.

 

INFORMATION REGARDING ACORDA

 

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.

 

Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s disease, post-stroke walking difficulties, migraine, and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

 

For more information, please visit www.acorda.com.